TIMP Engineering and Application to Arthritis

TIMP 工程及其在关节炎中的应用

• 批准号: 6611952
• 负责人: KEITH BREW
• 金额: $ 39.42万
• 依托单位: FLORIDA ATLANTIC UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-09-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6611952
• 关键词: SDS polyacrylamide gel electrophoresis; antiarthritic agent; articular cartilage; calorimetry; chondroitin sulfates; clinical research; collagenase; drug screening /evaluation; electrospray ionization mass spectrometry; enzyme activity; enzyme linked immunosorbent assay; enzyme therapy; human tissue; laboratory mouse; mass spectrometry; matrix assisted laser desorption ionization; metalloendopeptidases; osteoarthritis; pathologic process; polymerase chain reaction; protein binding; protein engineering; proteoglycan; rheumatoid arthritis; tissue inhibitor of metalloproteinases; western blottings

DESCRIPTION (provided by applicant): The matrix metalloproteinases (MMPs) are zinc metalloproteinases that degrade components of the extracellular matrix. They play major roles in diseases including arthritis, cancer and atherosclerosis. The activities of MMPs are regulated by endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs)-1, to -4. Our long-range goals are to understand how TIMPs inhibit MMPs and to use this information to engineer variant TIMPs that selectively inhibit individual or chosen groups of metalloproteinases. These targeted TIMPs will be tested for efficacy in alleviating the progression of diseases associated with increased degradation of the extracellular matrix. Our recent finding that TIMP-3 is a potent inhibitor of two aggrecanases (ADAMTS-4 and ADAMTS-5), key enzymes in the degradation of the cartilage proteoglycan, aggrecan, leads us to further investigate and test TIMP-3, and other TIMP variants, as inhibitors for preventing the progression of arthritis. To achieve these goals we will elucidate the structural basis of TIMP specificity for aggrecanases and MMPs and engineer TIMPs that are targeted for metalloproteinases involved in cartilage degradation. These inhibitors will be tested for effectiveness in ex vivo and in vivo models of rheumatoid arthritis (RA) and osteoarthritis (OA). The Specific Aims are: (1) to investigate the mechanism of inhibition of aggrecanases by TIMP-3 and generate specific inhibitors of these enzymes; (2) to produce TIMP variants that selectively inhibit collagenases (MMP-1 and -13), gelatinase A (MMP-2), or MT1-MMP; (3) identify and characterize low-molecular weight peptide inhibitors employing non-toxic variants of sarafotoxin, an analogue of the unique inhibitory region of TIMPs; (4) characterize the structural and physical basis of strong and specific metalloproteinase binding in TIMPs; (5) test recombinant TIMP-3 and other wild-type and variant TIMPs for their ability to prevent cartilage breakdown using the cartilage explant system; (6) test the efficacy of TIMP-3 and TIMP variants as potential blockers of cartilage degradation in the collagen-induced arthritis model of RA, and in the STR/ort mouse OA model; and (7) identify metalloproteases that act in articular cartilage breakdown during the progression of OA in humans. These studies will produce mechanistic and structural information about the interactions of TIMPs and metalloproteinases and new insights into therapeutic approaches for arthritis.

描述（由申请人提供）：基质金属蛋白酶（MMP）是锌金属蛋白酶，可降解细胞外基质的成分。他们在包括关节炎，癌症和动脉粥样硬化在内的疾病中起主要作用。 MMP的活性受内源性抑制剂，金属蛋白酶（TIMP）-1的组织抑制剂-1，至-4。我们的远程目标是了解TIMP如何抑制MMP并使用此信息来设计有选择地抑制个体或选择的金属蛋白酶组的变体TIMP。这些有针对性的TIMP将在减轻与细胞外基质降解有关的疾病进展方面的功效测试。我们最近的发现，TIMP-3是两种脂肪酶（ADAMTS-4和ADAMTS-5）的有效抑制剂，即在软骨蛋白聚糖降解的关键酶，Aggrecan，使我们导致我们进一步调查和测试TIMP-3，以及其他TIMP变体，以及其他抑制剂，以预防Aribytity的进展。为了实现这些目标，我们将阐明针对涉及软骨降解的金属蛋白酶的Aggrecanases和MMP和工程师TIMP的TIMP特异性的结构基础。这些抑制剂将在体内和体内类风湿关节炎（RA）和骨关节炎（OA）中的有效性进行测试。具体目的是：（1）研究TIMP-3抑制凝集酶的机制，并产生这些酶的特定抑制剂； （2）产生有选择地抑制胶原酶（MMP-1和-13），明胶酶A（MMP-2）或MT1-MMP的TIMP变体； （3）识别并表征了使用无毒变体的sarafotoxin的低分子重量肽抑制剂，Sarafotoxin是TIMPS独特抑制区域的类似物； （4）表征TIMP中强和特异性金属蛋白酶结合的结构和物理基础； （5）测试重组TIMP-3以及其他野生型和变体TIMP，以防止软骨外植体系统防止软骨破裂的能力； （6）测试TIMP-3和TIMP变体的功效，作为RA的胶原蛋白诱导的关节炎模型以及Str/Ort小鼠OA模型中软骨降解的潜在阻滞剂； （7）确定在人类OA进展过程中在关节软骨中作用的金属蛋白酶。这些研究将产生有关TIMP和金属蛋白酶相互作用的机械和结构信息，以及对关节炎治疗方法的新见解。